NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Wednesday’s 10 Top Performers. In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at ...

HighTower Advisors LLC decreased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 6.5% during the ...

We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...

Regenxbio (NASDAQ:RGNX) and Solid Biosciences (NASDAQ:SLDB) witnessed contrasting fortunes on Tuesday after Sarepta ...

Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...

Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported ...

Gene therapy developer Sarepta Therapeutics (NASDAQ:SRPT) lost ~25% in the premarket on Tuesday as the company disclosed the death of a patient treated with Elevidys, its FDA-approved treatment for ...

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Sarepta Therapeutics (BMV:SRPT) with a Sector Perform recommendation. There are 956 funds or institutions reporting positions ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the twenty-three ratings firms that are currently covering the firm ...